China Pharmaceutical Companies Strengthen Brand Building
This article was originally published in PharmAsia News
At the 58th PharmChina Exhibition held in Kunming, China, well-known local pharmaceutical companies such as Tong Ren Tang and Qingdao Huanghai Pharmaceutical had brand propaganda in mind rather than business. Upon establishing their distribution network, local corporations have to start building their brand names or they can easily lose their channels. With increasingly fierce competition, rivals can easily replicate products, quality, technology, management, channels, services and process, except brand names. China's new regulations on generic drug names and drug advertisements mean that name recognition will probably be the key factor that wins over customers. (Click here for more - Chinese Language)
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.